医薬品開発・製造受託市場：サービス、開発段階、エンドユーザー別-2025～2030年の世界予測

医薬品開発・製造受託市場の2023年の市場規模は1,257億3,000万米ドルで、2024年には1,362億7,000万米ドルに達すると予測され、CAGR 8.46%で成長し、2030年には2,220億4,000万米ドルに達すると予測されています。

医薬品開発・製造受託（CDMO）産業は、医療のサプライチェーンにおける重要なコンポーネントとして、あらゆる規模の製薬会社に医薬品開発、製造、包装などの必要不可欠なサービスを提供しています。その必要性は、製薬会社がコアコンピタンスに集中する一方で、CDMOの専門知識を活用して製品イノベーションを合理化し、医薬品をより効率的に市場に投入する必要性が高まっていることに起因しています。CDMOの適用範囲は、合成、製剤化、臨床検査、商業生産を含む医薬品製造のライフサイクル全体に及びます。主要な最終用途セグメントには、大手製薬会社、バイオテクノロジー企業、ジェネリック医薬品メーカーなどが含まれます。市場開拓の原動力となっているのは、生物製剤やバイオシミラーに対する需要の高まり、医薬品開発期間の短縮に対するプレッシャー、専門的な製造能力を必要とするアウトソーシングの増加といった要因です。最近のビジネス機会としては、細胞治療や遺伝子治療における能力の拡大、人工知能を活用したプロセスの最適化、戦略的パートナーシップの形成によるサービス提供の強化などが挙げられます。しかし、厳しい規制要件、高い初期投資コスト、生産スケジュールに影響を与えるサプライチェーンの混乱などの課題に直面しています。

新たな機会を捉えるために、CDMOは個別化医療や再生療法におけるオファリングの拡大に注力し、連続加工や3Dプリンティングのような最先端の製造技術に投資し、意思決定を改善するための強固なデータ分析能力を開発すべきです。さらに、技術・プロバイダーと提携することで、このセクターが直面するいくつかの技術的課題を克服することができます。先進的な製造インフラに必要な高額な資本支出や、世界の規制基準への準拠の維持には、しばしば限界がつきまとう。CDMO市場は本質的にダイナミックな市場であり、急速な技術進歩や顧客ニーズの進化を特徴としています。R&Dとイノベーションへの継続的な投資と戦略的パートナーシップの組み合わせにより、CDMOは既存と新たな課題を克服しながら持続的な成長を遂げることができます。

市場力学：急速に進化する医薬品開発・製造受託市場の主要な市場洞察を解明

医薬品開発・製造受託市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ジェネリック医薬品と生物学的治療に対する需要の高まり
  • 医薬品研究開発への投資の増加
  • CDMO数の増加とCDMOによる先端製造技術への投資の増加
• 市場抑制要因
  • シリアライゼーションの採用
• 市場機会
  • 核医療と特殊医薬品への注目の高まり
  • 細胞・遺伝子治療へのニーズの高まり
• 市場課題
  • 国によって異なる貿易施策

ポーターのファイブフォース：医薬品開発・製造受託市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：医薬品開発・製造受託市場における外部からの影響の把握

外部マクロ環境要因は、医薬品開発・製造受託市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：医薬品開発・製造受託市場における競合情勢の把握

医薬品開発・製造受託市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：医薬品開発・製造受託市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、医薬品開発・製造受託市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：医薬品開発・製造受託市場における成功への道筋を描く

医薬品開発・製造受託市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ジェネリック医薬品と生物学的療法の需要増加
    • 医薬品研究開発への投資増加
    • CDMO数の増加とCDMOによる先進製造技術への投資の増加
  • 抑制要因
    • シリアライゼーションの採用
  • 機会
    • 核医療と専門医薬品への注目が高まる
    • 細胞・遺伝子治療の需要の高まり
  • 課題
    • 国間の貿易施策の多様性
• 市場セグメンテーション分析
  • サービス：厳しい規制基準を遵守するために、エンドユーザーによるバイオ医薬品製造サービスの普及が増加
  • エンドユーザー：大手製薬会社は、複雑な医薬品開発を管理するために医薬品CDMOサービスを広く採用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 医薬品開発・製造受託市場：サービス別

• イントロダクション
• バイオ医薬品製造サービス
  • 生物製剤API製造サービス
  • バイオロジクスFDF製造サービス
• 医薬品開発サービス
• 医薬品製造サービス
  • 医薬品API製造
    • カプセル製造サービス
    • 経口液剤製造サービス
    • 非経口/注射剤製造サービス
    • タブレット製造サービス
  • 医薬品FDF製造
• 二次包装サービス

第7章 医薬品開発・製造受託市場：開発段階別

• イントロダクション
• フェーズI臨床検査
• フェーズII臨床検査
• フェーズIII臨床検査
• フェーズIV臨床検査
• 前臨床

第8章 医薬品開発・製造受託市場：エンドユーザー別

• イントロダクション
• バイオテクノロジー企業
• ジェネリック医薬品会社
• 製薬会社
  • 大手製薬会社
  • 専門医薬品
• 中小規模の製薬会社

第9章 南北アメリカの医薬品開発・製造受託市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の医薬品開発・製造受託市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの医薬品開発・製造受託市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • AGC BiologicsとBioConnectionは協力して、エンドツーエンドのバイオ医薬品開発と製造ソリューションを提供し、効率を高め、市場投入を迅速化
  • Kuhne Holding AGはBC PartnersからAenova Groupの過半数の株式を取得し、リソースを活用して成長とイノベーションを強化
  • Alcami、西海岸に拠点を置くPacific Pharmaceutical Servicesの買収を発表
  • Piramal Pharma、事業拡大のため100億インドルピーを投資
  • eXmoor Pharma、GMP施設の開設により細胞・遺伝子治療のフルサービスCDMOパートナーに拡大
• 戦略分析と提言

企業一覧

• AbbVie, Inc.
• Acino International AG
• Aenova Holding GmbH
• Akums Drugs& Pharmaceuticals Ltd
• Almac Group Limited
• Aurobindo Pharma Limited
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Catalent, Inc.
• Curia Global, Inc.
• Danaher Corporation
• Delwis Healthcare Pvt. Ltd.
• Evonik Industries AG
• Fabbrica Italiana Sintetici S.p.A.
• Famar Health Care Services
• FUJIFILM Diosynth BIoTechnologies U.S.A., Inc.
• Gerresheimer AG
• Grifols S.A.
• Hikal Ltd
• Hovione
• Jubilant Pharmova Limited
• Lonza Group AG
• Pfizer Inc.
• Porton Pharma Solutions Ltd.
• Recipharm AB
• Samsung Biologics Co., Ltd.
• Siegfried AG
• The Fareva Group
• Thermo Fisher Scientific Inc.
• Vetter Pharma-Fertigung GmbH & Co. KG
• WuXi Biologics Co., Ltd.

LIST OF FIGURES

• FIGURE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET DYNAMICS
• TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CAPSULE MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ORAL LIQUID MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PARENTERAL/INJECTABLE MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TABLET MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL FDF MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE IV CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SPECIALTY PHARMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SMALL & MID-SIZE PHARMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 59. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 60. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 61. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 62. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 63. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 64. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 96. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 97. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 98. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 99. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 100. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 101. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 103. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 104. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 105. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 106. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 107. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 108. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 223. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 224. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 225. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 226. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 227. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 228. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 229. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
• TABLE 241.

The Pharmaceutical Contract Development & Manufacturing Market was valued at USD 125.73 billion in 2023, expected to reach USD 136.27 billion in 2024, and is projected to grow at a CAGR of 8.46%, to USD 222.04 billion by 2030.

The pharmaceutical contract development and manufacturing (CDMO) industry serves as a critical component in the healthcare supply chain, providing essential services such as drug development, manufacturing, and packaging to pharmaceutical companies of all sizes. Its necessity stems from the increasing need for pharmaceutical firms to focus on their core competencies while leveraging CDMO expertise to streamline product innovation and bring drugs to market more efficiently. The application scope of CDMOs spans the entire drug production lifecycle, including synthesis, formulation, clinical trials, and commercial manufacturing. Key end-use segments include large pharma companies, biotech firms, and generic drug producers. Market growth is fueled by factors such as rising demand for biologics and biosimilars, the pressure to reduce drug development time, and an increase in outsourcing activities driven by the need for specialized manufacturing capabilities. Recent opportunities include expanding capabilities in cell and gene therapies, leveraging artificial intelligence for process optimization, and forming strategic partnerships to enhance service offerings. However, the market faces challenges such as stringent regulatory requirements, high initial investment costs, and supply chain disruptions impacting production timelines.

To capture emerging opportunities, CDMOs should focus on expanding their offerings in personalized medicine and regenerative therapies, invest in cutting-edge manufacturing technologies like continuous processing and 3D printing, and develop robust data analytics capabilities for improved decision-making. Moreover, forming alliances with technology providers can help overcome some technological challenges faced by the sector. Limitations are often related to the high capital expenditure required for advanced manufacturing infrastructure and maintaining compliance with global regulatory standards. The CDMO market is inherently dynamic, characterized by rapid technological advancements and evolving client demands, making it critical for companies to remain agile and forward-thinking. Continuous investment in R&D and innovation, paired with strategic partnerships, can position CDMOs for sustained growth while navigating existing and emerging challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmaceutical Contract Development & Manufacturing Market

The Pharmaceutical Contract Development & Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising Demand for Generics and Biological Therapies
  • Increasing Investments in Pharmaceutical R&D
  • Increasing Number of CDMOs and Rising Investments in Advanced Manufacturing Technologies by CDMOs
• Market Restraints
  • Introduction of Serialization
• Market Opportunities
  • Increasing Focus on Nuclear Medicine and Specialty Drugs
  • Growing need for Cell and Gene Therapies
• Market Challenges
  • Variable Trade Policies Between Countries

Porter's Five Forces: A Strategic Tool for Navigating the Pharmaceutical Contract Development & Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmaceutical Contract Development & Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmaceutical Contract Development & Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmaceutical Contract Development & Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmaceutical Contract Development & Manufacturing Market

A detailed market share analysis in the Pharmaceutical Contract Development & Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmaceutical Contract Development & Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmaceutical Contract Development & Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmaceutical Contract Development & Manufacturing Market

A strategic analysis of the Pharmaceutical Contract Development & Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Contract Development & Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Acino International AG, Aenova Holding GmbH, Akums Drugs& Pharmaceuticals Ltd, Almac Group Limited, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Curia Global, Inc., Danaher Corporation, Delwis Healthcare Pvt. Ltd., Evonik Industries AG, Fabbrica Italiana Sintetici S.p.A., Famar Health Care Services, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Gerresheimer AG, Grifols S.A., Hikal Ltd, Hovione, Jubilant Pharmova Limited, Lonza Group AG, Pfizer Inc., Porton Pharma Solutions Ltd., Recipharm AB, Samsung Biologics Co., Ltd., Siegfried AG, The Fareva Group, Thermo Fisher Scientific Inc., Vetter Pharma-Fertigung GmbH & Co. KG, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Contract Development & Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Service, market is studied across Biologics Manufacturing Services, Drug Development Services, Pharmaceutical Manufacturing Services, and Secondary Packaging Services. The Biologics Manufacturing Services is further studied across Biologics API Manufacturing Services and Biologics FDF Manufacturing Services. The Pharmaceutical Manufacturing Services is further studied across Pharmaceutical API Manufacturing and Pharmaceutical FDF Manufacturing. The Pharmaceutical API Manufacturing is further studied across Capsule Manufacturing Services, Oral Liquid Manufacturing Services, Parenteral/Injectable Manufacturing Services, and Tablet Manufacturing Services.
• Based on Development Stage, market is studied across Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, Phase IV Clinical Trials, and Preclinical.
• Based on End User, market is studied across Biotechnology Companies, Generic Pharmaceutical Companies, Pharmaceutical Companies, and Small & Mid-Size Pharma. The Pharmaceutical Companies is further studied across Big Pharma and Specialty Pharma.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising Demand for Generics and Biological Therapies
    • 5.1.1.2. Increasing Investments in Pharmaceutical R&D
    • 5.1.1.3. Increasing Number of CDMOs and Rising Investments in Advanced Manufacturing Technologies by CDMOs
  • 5.1.2. Restraints
    • 5.1.2.1. Introduction of Serialization
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing Focus on Nuclear Medicine and Specialty Drugs
    • 5.1.3.2. Growing need for Cell and Gene Therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Variable Trade Policies Between Countries
• 5.2. Market Segmentation Analysis
  • 5.2.1. Service: Rising penetration of biologics manufacturing services by end-users to adhere to stringent regulatory standards
  • 5.2.2. End User: Big pharma companies widely adopting pharmaceutical CDMO services to manage complex drug development
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pharmaceutical Contract Development & Manufacturing Market, by Service

• 6.1. Introduction
• 6.2. Biologics Manufacturing Services
  • 6.2.1. Biologics API Manufacturing Services
  • 6.2.2. Biologics FDF Manufacturing Services
• 6.3. Drug Development Services
• 6.4. Pharmaceutical Manufacturing Services
  • 6.4.1. Pharmaceutical API Manufacturing
    • 6.4.1.1. Capsule Manufacturing Services
    • 6.4.1.2. Oral Liquid Manufacturing Services
    • 6.4.1.3. Parenteral/Injectable Manufacturing Services
    • 6.4.1.4. Tablet Manufacturing Services
  • 6.4.2. Pharmaceutical FDF Manufacturing
• 6.5. Secondary Packaging Services

7. Pharmaceutical Contract Development & Manufacturing Market, by Development Stage

• 7.1. Introduction
• 7.2. Phase I Clinical Trials
• 7.3. Phase II Clinical Trials
• 7.4. Phase III Clinical Trials
• 7.5. Phase IV Clinical Trials
• 7.6. Preclinical

8. Pharmaceutical Contract Development & Manufacturing Market, by End User

• 8.1. Introduction
• 8.2. Biotechnology Companies
• 8.3. Generic Pharmaceutical Companies
• 8.4. Pharmaceutical Companies
  • 8.4.1. Big Pharma
  • 8.4.2. Specialty Pharma
• 8.5. Small & Mid-Size Pharma

9. Americas Pharmaceutical Contract Development & Manufacturing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Pharmaceutical Contract Development & Manufacturing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Pharmaceutical Contract Development & Manufacturing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. AGC Biologics and BioConnection join forces to provide end-to-end biopharmaceutical development and manufacturing solutions, enhancing efficiency and speeding up market delivery.
  • 12.3.2. Kuhne Holding AG acquires majority stake in Aenova Group from BC Partners, leveraging resources for enhanced growth and innovation
  • 12.3.3. Alcami Announces Acquisition of West-Coast-Based Pacific Pharmaceutical Services
  • 12.3.4. Piramal Pharma to Invest INR 1,000 Crore for Expansion
  • 12.3.5. eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie, Inc.
• 2. Acino International AG
• 3. Aenova Holding GmbH
• 4. Akums Drugs& Pharmaceuticals Ltd
• 5. Almac Group Limited
• 6. Aurobindo Pharma Limited
• 7. Boehringer Ingelheim International GmbH
• 8. Cambrex Corporation
• 9. Catalent, Inc.
• 10. Curia Global, Inc.
• 11. Danaher Corporation
• 12. Delwis Healthcare Pvt. Ltd.
• 13. Evonik Industries AG
• 14. Fabbrica Italiana Sintetici S.p.A.
• 15. Famar Health Care Services
• 16. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• 17. Gerresheimer AG
• 18. Grifols S.A.
• 19. Hikal Ltd
• 20. Hovione
• 21. Jubilant Pharmova Limited
• 22. Lonza Group AG
• 23. Pfizer Inc.
• 24. Porton Pharma Solutions Ltd.
• 25. Recipharm AB
• 26. Samsung Biologics Co., Ltd.
• 27. Siegfried AG
• 28. The Fareva Group
• 29. Thermo Fisher Scientific Inc.
• 30. Vetter Pharma-Fertigung GmbH & Co. KG
• 31. WuXi Biologics Co., Ltd.